The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study.

Bibliographic Details
Title:	The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study.
Authors:	Knox-Brown, Ben¹ (AUTHOR) b.knox-brown20@imperial.ac.uk, Patel, Jaymini¹ (AUTHOR), Potts, James¹ (AUTHOR), Ahmed, Rana² (AUTHOR), Aquart-Stewart, Althea³ (AUTHOR), Barbara, Cristina^4,5 (AUTHOR), Buist, A. Sonia⁶ (AUTHOR), Cherkaski, Hamid Hacene⁷ (AUTHOR), Denguezli, Meriam⁸ (AUTHOR), Elbiaze, Mohammed⁹ (AUTHOR), Erhabor, Gregory E.¹⁰ (AUTHOR), Franssen, Frits M. E.^11,12 (AUTHOR), Al Ghobain, Mohammed¹³ (AUTHOR), Gislason, Thorarinn^14,15 (AUTHOR), Janson, Christer¹⁶ (AUTHOR), Kocabaş, Ali¹⁷ (AUTHOR), Mannino, David^18,19 (AUTHOR), Marks, Guy^20,21,22 (AUTHOR), Mortimer, Kevin^23,24 (AUTHOR), Nafees, Asaad Ahmed²⁵ (AUTHOR)
Superior Title:	Respiratory Research. 5/23/2023, Vol. 24 Issue 1, p1-15. 15p.
Subject Terms:	RESPIRATORY obstructions, OBSTRUCTIVE lung diseases, HEART metabolism disorders, COUGH, SYMPTOMS, FORCED expiratory volume
Abstract:	Background: Spirometric small airways obstruction (SAO) is common in the general population. Whether spirometric SAO is associated with respiratory symptoms, cardiometabolic diseases, and quality of life (QoL) is unknown. Methods: Using data from the Burden of Obstructive Lung Disease study (N = 21,594), we defined spirometric SAO as the mean forced expiratory flow rate between 25 and 75% of the FVC (FEF25-75) less than the lower limit of normal (LLN) or the forced expiratory volume in 3 s to FVC ratio (FEV3/FVC) less than the LLN. We analysed data on respiratory symptoms, cardiometabolic diseases, and QoL collected using standardised questionnaires. We assessed the associations with spirometric SAO using multivariable regression models, and pooled site estimates using random effects meta-analysis. We conducted identical analyses for isolated spirometric SAO (i.e. with FEV1/FVC ≥ LLN). Results: Almost a fifth of the participants had spirometric SAO (19% for FEF25-75; 17% for FEV3/FVC). Using FEF25-75, spirometric SAO was associated with dyspnoea (OR = 2.16, 95% CI 1.77–2.70), chronic cough (OR = 2.56, 95% CI 2.08–3.15), chronic phlegm (OR = 2.29, 95% CI 1.77–4.05), wheeze (OR = 2.87, 95% CI 2.50–3.40) and cardiovascular disease (OR = 1.30, 95% CI 1.11–1.52), but not hypertension or diabetes. Spirometric SAO was associated with worse physical and mental QoL. These associations were similar for FEV3/FVC. Isolated spirometric SAO (10% for FEF25-75; 6% for FEV3/FVC), was also associated with respiratory symptoms and cardiovascular disease. Conclusion: Spirometric SAO is associated with respiratory symptoms, cardiovascular disease, and QoL. Consideration should be given to the measurement of FEF25-75 and FEV3/FVC, in addition to traditional spirometry parameters. [ABSTRACT FROM AUTHOR]
	Copyright of Respiratory Research is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Academic Search Premier
Full text is not displayed to guests.	Login for full access.

Description
Description not available.